Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 50Ovarian Neoplasms 43Lung Neoplasms 41Fallopian Tube Neoplasms 29Carcinoma, Ovarian Epithelial 28Breast Neoplasms 22Neuroblastoma 18Adenocarcinoma of Lung 17Central Nervous System Neoplasms 16Brenner Tumor 12Endometrial Neoplasms 9Adenocarcinoma, Bronchiolo-Alveolar 9Testicular Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Astrocytoma 8Unspecified Adult Solid Tumor, Protocol Specific 7Triple Negative Breast Neoplasms 7Oligodendroglioma 7Lymphoma, Large B-Cell, Diffuse 7Brain Neoplasms 7Head and Neck Neoplasms 6Teratoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Melanoma 5Medulloblastoma 5Leukemia, Myeloid, Acute 5Gliosarcoma 5Glioblastoma 5Thrombocythemia, Essential 4Testicular Germ Cell Tumor 4

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Advanced NUT Carcinoma × Carboplatin × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡